The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Open accessAbstract
BACKGROUND: Epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins) represent approximately 10% of EGFR-mutant lung adenocarcinomas, and are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Clinical outcomes in comparison with patients with sensitizing EGFR mutations are not well established. METHODS: Patients with stage IV lung adenocarcinomas with EGFR exon20ins were identified through routine molecular testing. Clinicopathologic data were collected. Overall survival (OS) was measured from the diagnosis of stage IV disease, and in patients treated with EGFR TKIs, the time to progression (TTP) on erlotinib was measured. RESULTS: One thousand eight hundred and eighty-two patients with stage IV lung adenocarcinomas were identified: 46 patients had EGFR exon20ins (2%), and 258 patients had an EGFR exon 19 deletion (exon19del)/L858R point mutation (14%). Among 11 patients with lung adenocarcinomas with EGFR exon20ins who received erlotinib, 3 patients (27%) had a partial response (FQEA, 1; ASV, 1; and unknown variant, 1). TTP for patients with EGFR exon20ins and patients with EGFR exon19del/L858R on erlotinib were 3 and 12 months, respectively (P < .01). Responses to chemotherapy were similar for patients with lung adenocarcinomas with EGFR exon20ins and patients with lung adenocarcinomas with EGFR exon19del/L858R. Median OS from the diagnosis of stage IV disease for patients with EGFR exon20ins and patients with EGFR exon19del/L858R was 26 months (95% confidence interval, 19 months-not reached n = 46) and 31 months (95% confidence interval, 28-33 months; n = 258), respectively (P = .53). CONCLUSIONS: The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR TKI therapy. Standard chemotherapy should be used as first-line therapy. These patients have an OS similar to that of patients with sensitizing EGFR mutations. Individuals with certain variants such as FQEA and ASV may respond to erlotinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Available treatment outcomes demonstrated lack of response to first- and second-generation EGFR TKIs such as erlotinib, gefitinib and afatinib, consistent with other series”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [19]
In the citing paper
“A review of 84 patients with exon 20 insertions across different series treated with either gefitinib or erlotinib demonstrated a RR of only 11% with a PFS of 2.4 months (12).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [12]
In the citing paper
“EGFR Ex20Ins tumors are generally unresponsive to 1st and 2nd generation EGFR inhibitors”
From Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions (2018) · cites this paper as [6]
In the citing paper
“These patients may experience a higher overall response rate (ORR) (58–63%) and a longer PFS (six months) with platinum-doublet chemotherapy, as reported in small retrospective studies [70,71].”
In the citing paper
“Patients harboring exon 20 insertions are associated with an ORR of 0–11% and a median progression-free survival (PFS) of 2–3 months when treated with first- or second-generation EGFR TKIs [19,21,37,44,45,70]”
In the citing paper
“Several studies, although very small, have shown that 1G EGFR‐TKI are less effective in patients with NSCLC harboring such uncommon EGFR mutations, compared with patients harboring common EGFR mutations.”
In the citing paper
“In a compilation of data on the treatment response to 1G‐TKI, ORR was only 17% (10/59) (Table 3).61, 62, 63, 64, 65”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 212
Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 17
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC
Passiglia, F., Malapelle, U., Normanno, N., & Pinto, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102438 · Cited by 16
Zheng, H., Zhang, H., Zhang, T., Wang, Q., Hu, F., & Li, B. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3460 · Cited by 16
Asaka, S., Yoshizawa, A., Saito, K., Kobayashi, Y., Yamamoto, H., Negishi, T., Nakata, R., Matsuda, K., Yamaguchi, A., & Honda, T. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4334 · Cited by 16
Park, S., Lee, S. Y., Kim, D.-J., Sim, Y. S., Ryu, J., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · BMC Cancer · doi:10.1186/s12885-020-07765-6 · Cited by 18
Cai, Y., Wang, X., Guo, Y., Sun, C., Xu, Y., Qiu, S., & Ma, K. (2019) · Medicine · doi:10.1097/md.0000000000013890 · Cited by 15
Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
Chen, H., Hu, S., Patterson, A. V., Smaill, J. B., Ding, K., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00875 · Cited by 14
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Zhang, S., Xu, F., Lei, S., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4852 · Cited by 13
TAS2940 , a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
Oguchi, K., Araki, H., Tsuji, S., Nakamura, M., Miura, A., Funabashi, K., Osada, A., Tanaka, S., Suzuki, T., Kobayashi, S. S., et al. (2022) · Cancer Science · doi:10.1111/cas.15617 · Cited by 12
Ho, K., Toh, C., Li, S., Liu, C., Yang, C., Lin, Y.-J., Su, T.-P., Wang, C., & Yen, T. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4210-1 · Cited by 13
Cai, Y., Wang, Y., Sun, J., Wang, X., Xu, Y., Sun, C., Guo, Y., Sun, M., & Ma, K. (2020) · Journal of International Medical Research · doi:10.1177/0300060520928793 · Cited by 13
Kobayashi, I. S., Viray, H., Rangachari, D., Kobayashi, S. S., & Costa, D. B. (2021) · Cells · doi:10.3390/cells10123561 · Cited by 12
Ito, K., Nishio, M., Kato, M., Murakami, H., Aoyagi, Y., Ohe, Y., Okayama, T., Hashimoto, A., Ohsawa, H., Tanaka, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0645 · Cited by 12
Le, X., Robichaux, J. P., Nilsson, M. B., Vijayan, R. S. K., Ravichandran, A., Wu, J., Elamin, Y. Y., Hong, L., Pei, J., He, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61817-8 · Cited by 12
Okahisa, M., Udagawa, H., Matsumoto, S., Kato, T., Yokouchi, H., Furuya, N., Kanemaru, R., Toyozawa, R., Nishiyama, A., Ohashi, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107798 · Cited by 12
Shah, V. S., McNatty, A., Simpson, L., Ofori, H., & Raheem, F. (2023) · Biomedicines · doi:10.3390/biomedicines11030950 · Cited by 12
Pan, B., Liang, J., Shi, H., Rao, K., Guo, W., & Zhan, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15127 · Cited by 9
Köhler, J., & Janne, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01494 · Cited by 11
Asaka, S., Yoshizawa, A., Nakata, R., Negishi, T., Yamamoto, H., Shiina, T., Shigeto, S., Matsuda, K., Kobayashi, Y., & Honda, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.7464 · Cited by 10
Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10
Zeng, L., Song, L., Liu, L., Wu, F., Xu, Q., Yan, H., Lin, S., Jiang, W., Wang, Z., Li, D., et al. (2024) · Med · doi:10.1016/j.medj.2024.02.011 · Cited by 9
Urbán, L., Dóczi, R., Vodicska, B., Tihanyi, D., Horváth, M., Kormos, D., Takács, I., Pápai-Székely, Z., Póka-Farkas, Z., Várkondi, E., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.005 · Cited by 10
Yang, G., Yang, Y., Hu, J., Xu, H., Zhang, S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984503 · Cited by 11
Clinical Trials in Precision Oncology
Mockus, S. M., Patterson, S. E., Statz, C. M., Bult, C. J., & Tsongalis, G. J. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.247437 · Cited by 9
Sekine, A., Katano, T., Oda, T., Ikeda, S., Iwasawa, T., Satoh, H., Kataoka, T., Okudela, K., & Ogura, T. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1730 · Cited by 9
Xie, C., Kong, J., Miao, F., Wang, X., & Sheng, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13487 · Cited by 9
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC
Rossi, S., Damiano, P., Toschi, L., Finocchiaro, G., Giordano, L., Marinello, A., Bria, E., D’Argento, E., & Santoro, A. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100787 · Cited by 9
Chen, L., Shih, J., Yu, C., & Yang, C. (2019) · Respirology Case Reports · doi:10.1002/rcr2.425 · Cited by 8
Zhao, H., Beyett, T. S., Jiang, J., Rana, J. K., Schaeffner, I. K., Santana, J., Janne, P. A., & Eck, M. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417144121 · Cited by 8
Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02377 · Cited by 8
Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Zhang, P., Nguyen, D., & Neal, J. W. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107186 · Cited by 8
van Veggel, B. A. M. H., van der Wekken, A. J., Paats, M. S., Hendriks, L. E. L., Hashemi, S. M. S., Daletzakis, A., van den Broek, D. A., Bosch, L. J. W., Monkhorst, K., Smit, E. F., et al. (2023) · Cancer · doi:10.1002/cncr.35090 · Cited by 8
Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial
Ito, K., & Hataji, O. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.52 · Cited by 7
Al‐Huseini, I., Sirasanagandla, S. R., Babu, K. S., Sofin, R. G. S., & Das, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220117114306 · Cited by 8
Jiang, W., Sha, M., & Chen, C. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001504 · Cited by 8
Jatkoe, T. A., Wang, S., Odegaard, J. I., Roth, A. M. V., Osgood, D., Martinez, G., Lucas, P., Curtin, J. C., & Karkera, J. D. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.07.003 · Cited by 8
Zhang, X., Han, H., Zhao, J., Liu, X., Zhang, J., Sun, R., Li, S., Liu, B., Zhu, H., Jiao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964606 · Cited by 8
Du, Z., Sun, J., Zhang, Y., Hesilaiti, N., Xia, Q., Cui, H., Fan, N., & Xu, X. (2023) · Biomolecules · doi:10.3390/biom13020210 · Cited by 9
Amivantamab: A narrative drug review
John, A., Noronha, V., Singh, A. K., Menon, N. S., & Prabhash, K. (2023) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_166_23 · Cited by 8
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?
Ricciuti, B., & Awad, M. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000489 · Cited by 9
Man, X., Sun, X., Chen, C., Xiang, Y., Zhang, J., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1367204 · Cited by 7
Han, H., Zhang, X., Liu, X., Zhao, J., Zhang, J., Zhang, J., Zhu, H., Jiao, S., & Tang, H. (2023) · Medicine · doi:10.1097/md.0000000000036667 · Cited by 7
Kanaoka, K., Tamiya, A., Inagaki, Y., Taniguchi, Y., Nakao, K., Takeda, M., Matsuda, Y., Okishio, K., & Shimizu, S. (2023) · Anticancer Research · doi:10.21873/anticanres.16445 · Cited by 7
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
Sangwan, K., & Agarwal, G. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01588-7 · Cited by 6
Lee, S. H., Jeong, H., Kim, D. H., Jang, S. J., Kim, S., Yoon, S., & Lee, K. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1177 · Cited by 6
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations
Sabari, J. K., Heymach, J. V., & Sandy, B. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0200 · Cited by 6
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
Asaka, S., Yoshizawa, A., Matsuda, K., Yamaguchi, A., Yamamoto, H., Shiina, T., Nakata, R., Ogawa, K., Zhang, M., & Honda, T. (2016) · Oncology Reports · doi:10.3892/or.2016.5287 · Cited by 6
Ma, Y., Liu, H., Zhang, M., Liu, B., Ding, Q., Zhang, L., Guo, L., & Liu, M. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-321 · Cited by 6
Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7
Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment
Bílek, O., Holánek, M., Berkovcová, J., Horký, O., Kazda, T., Čoupková, H., Špelda, S., Kristková, L., Zvaríková, M., Podhorec, J., et al. (2019) · Klinicka onkologie · doi:10.14735/amko20193s6 · Cited by 7
Current paradigm of EGFR in non-small cell lung cancer: A long way forward
Miyamura, B. V., Mambetsariev, I., Fricke, J., Arias-Romero, J., Cadman, K., Shrestha, S., Pisick, E. P., Nguyen, D., Malhotra, J. D., Reyes, A., et al. (2025) · Med · doi:10.1016/j.medj.2025.100803 · Cited by 5
Been, K. W., Kang, S., Bae, T., Hong, S., Kim, G., Hur, J. K., Hwang, W., & Chang, B. (2025) · Cancers · doi:10.3390/cancers17203343 · Cited by 5
Targeting exon 20 insertion mutations in lung cancer
Yang, Y., & Wang, Y. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000919 · Cited by 5
Zhu, L., Liu, Y., Gao, H., Liu, J., Zhou, Q., & Luo, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.755135 · Cited by 5
Yao, Y., Chu, H., Wang, J., & Wang, B. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3835 · Cited by 5
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
Drug Resistance and Novel Targets for Cancer Therapy: An Overview of Recent Findings
Ouverney, G., Hottz, D., & Robbs, B. K. (2024) · Biomedicines · doi:10.3390/biomedicines12040816 · Cited by 5
Fan, F., Zhou, M., Ye, X., Mo, Z., Ma, Y., Luo, L., Liang, X., Liu, H., Weng, Y., Lin, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100961 · Cited by 4
Garzón‐Ibáñez, M., Reyes, R., Molina‐Vila, M. Á., & Sullivan, I. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03899-w · Cited by 4
Tang, D., Jiang, H., Li, Z., Gao, W. Y., & Sun, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_200530n586 · Cited by 4
Deng, Y., Yang, C., Liu, W., Cai, S., & Guo, X. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001274 · Cited by 4
Kandemir, E. A. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221112015 · Cited by 5
Pierret, T., Greillier, L., Guisier, F., Daniel, C., Descourt, R., Galland, L., Molinier, O., Decroisette, C., Cortot, A. B., Moreau, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108766 · Cited by 3
Varachev, V. O., Susova, O. Y., Mitrofanov, A. A., Krasnov, G. S., Насхлеташвили, Д. Р., Ammour, Y. I., Bezhanova, S. D., Sevyan, N. V., Прозоренко, Е. В., Bekyashev, A. К., et al. (2024) · Advances in molecular oncology · doi:10.17650/2313-805x-2024-11-3-68-78 · Cited by 3
Ikeuchi, T., Tokuyasu, H., & Ishikawa, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0927-18 · Cited by 3
Zhang, W., & Dong, X. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211044980 · Cited by 3
Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3
Yang, S., Jiang, Z., & Lu, H. (2017) · PubMed Central · Cited by 3
Furuya, N. (2025) · Future Oncology · doi:10.1080/14796694.2025.2550927 · Cited by 2
Stencel, K. M., Wasąg, B., Pruszko, C., Dąbrowska, K., Książek, P., Dziadek, K., Bryl, M., & Krzakowski, M. J. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0044 · Cited by 2
Udovičić-Gagula, D., Dzananovic, N., & Dorić, M. (2023) · Medicinski Glasnik · doi:10.17392/1627-23 · Cited by 2
NovelEGFRmutations in diffuse midline gliomas using cost-effective strategies: A report of 2 cases
Dandapath, I., Sahu, S., Bhardwaj, S., Mohan, T., Chakraborty, R., Singh, J., Singh, S., Garg, A. K., Gupta, D. K., Sharma, M. C., et al. (2024) · Neuro-Oncology Practice · doi:10.1093/nop/npae008 · Cited by 2
Zhang, M.-S., Yeh, Y., Huang, H., Lin, L.-W., Huang, Y.-L. O., Wang, L., Yao, L.-J., Hung, T.-C., Tseng, Y., Lee, Y., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301120 · Cited by 2
Suay, G., Martín-Martorell, P., Aparisi, F., Arnal, M., Guirado, M., Azkárate, A., Garde, J., Cumplido-Burón, J. D., Insa, A., González, J., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03776-y · Cited by 2
Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma
Inagaki, Y., Tamiya, A., Matsuda, Y., Azuma, K., Adachi, Y., Enomoto, T., Kouno, S., Taniguchi, Y., Saijo, N., Okishio, K., et al. (2020) · Medicine · doi:10.1097/md.0000000000022628 · Cited by 2
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2
Kim, Y. J., Kim, S., Kim, T. M., Suh, K. J., Kim, M., Kim, S. H., Keam, B., Kim, D., Lee, J. S., & Heo, D. S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107870 · Cited by 3
Shen, L., Hu, G., Wang, Y., Zhao, J., Li, X., Zhuo, J., Low, G. K. M., & Lu, S. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03826-3 · Cited by 1
Haider, E., Akhtar, I., Taj, J., & Ekouo, J. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004137 · Cited by 1
Wen, Q., Zhuang, Y., Fu, S., Pan, C., Liu, Z., & Wang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1707050 · Cited by 1
Lau, L. Y., Sahib, N. R. B. M., Cangco, C. Y. P., & Tan, A. C. (2026) · Drugs · doi:10.1007/s40265-026-02329-7 · Cited by 1
Passiglia, F., Passaro, A., Gariazzo, E., Montrone, M., Pasello, G., Tiseo, M., Russano, M., Citarella, F., Muscarella, L. A., Pozzessere, D., et al. (2026) · Cancer · doi:10.1002/cncr.70476 · Cited by 1
Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
Wang, Y., & Arulananda, S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100477 · Cited by 1
Matsuura, S., Morikawa, K., Ito, Y., Kagoo, N., Kubota, T., Ichijo, K., Mochizuki, E., Uehara, M., Harada, M., Tsukui, M., et al. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101236 · Cited by 1
NSCLC: EGFR-Exon-20-Insertionen im Visier
von Kieseritzky, K. (2015) · Im Focus Onkologie · doi:10.1007/s15015-015-2218-y
EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?
Haraguchi, M., & Takahashi, K. (2018) · Respiratory disease series · doi:10.1007/978-981-10-8144-6_15
Molekularpathologie des Lungenkarzinoms: aktuelle Standards und weitere Entwicklungen
Falk, M., Schatz, S., & Heukamp, L. C. (2019) · Der Pneumologe · doi:10.1007/s10405-019-00275-8
[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency
Çelik, E., Samancı, N. Ş., Karadağ, M., Demirci, N. S., Çıkman, D. İ., Derin, S., Bedir, Ş., Değerli, E., Oruç, K., Öztaş, N. Ş., et al. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220964895
朱, 文. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111792
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations
Addeo, A. (2022) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2022.12.071
Drug Resistance in Lung Cancer
Colarusso, C., Terlizzi, M., Pinto, A., & Sorrentino, R. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_62
Yoh, K., Azuma, K., Hayashi, H., Nishio, M., Chikamori, K., Ichihara, E., Watanabe, Y., Asato, T., Kitagawa, T., Fram, R. J., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02588-y · Cited by 1
Hanley, M. J., Zhang, S., Pavlakis, N., Soo, R. A., van der Wekken, A. J., Ganju, V., Piña, A., Dong, Q., & Gupta, N. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1500
Wang, K.-Y., Chang, S.-C., Wei, Y., Hung, J.-C., Chen, C., & Chang, C. (2025) · Current Oncology · doi:10.3390/curroncol32030174
Liu, K., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2025) · Science Progress · doi:10.1177/00368504251325406
Masui, Y., Masuda, K., & Yoshida, T. (2025) · Haigan · doi:10.2482/haigan.65.71
Premature Deaths and Life-Years Lost From Lack of Amivantamab in Brazil's Unified Health System
Lenz, G., Pereira, R. A., Schwengber, W. K., Tumelero, M., Peruzzo, N., Lago, L. S., & Lopes, G. D. L., Jr. (2025) · JCO Global Oncology · doi:10.1200/go-25-00302
Metadata
- Authors
- Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York
- Department of Pathology Memorial Sloan Kettering Cancer Center New York New York
- Corresponding author
- Naidoo, Jarushka
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-06-10
- Volume
- 121
- Issue
- 18
- Pages
- 3212-3220
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC4807634
- OpenAlex
- W1566300951
- Cited by
- 211
- References
- 37
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 17 · 2023: 19 · 2022: 29 · 2021: 34 · 2020: 28 · 2019: 13 · 2018: 21 · 2017: 11 · 2016: 10 · 2015: 2
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA129243, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- EGFR exon 20 insertion, lung adenocarcinoma, erlotinib, EGFR tyrosine kinase inhibitors, EGFR exon 19 deletion, L858R mutation, EGFR mutation, treatment resistance, overall survival, time to progression, first-line chemotherapy, advanced lung cancer, clinical outcomes, molecular testing, targeted therapy response
- MeSH terms
- Erlotinib Hydrochloride, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Agents, Exons, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutagenesis, Insertional, Treatment Outcome, Genes, erbB-1, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
